The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Covalon Technologies Ltd.

Monday Deal Review: November 11, 2013

  Welcome to your Monday Biotech Deal Review for November 11, 2013! This week’s big story was the announcement that Paladin Labs has agreed to be acquired by NASDAQ-listed Endo Health Solutions for $1.7 billion. The deal will lead to existing Paladin shareholders recieving shares in a new holding company (holding both Endo and Paladin shares) and newly formed Canadian public company Knight Therepeutics.

There were many more notable deals this past week, so follow the link to see the full week’s worth of major biotech stories!

Read more of this post

Monday Deal Review: August 19, 2013

Welcome to your Monday Biotech Deal Review for August 19, 2013! As August comes to a close, activity is beginning to pick up.  Bellus and Valeant have closed their acquisitions of Thallion and Bausch + Lomb, respectively.  On the financing side of things, Sophiris and Covalon are pursuing offerings, with Sophiris looking at rasing $65 million.  Finally, Transition, Vivione and Quest PharmaTech have executed deals for licensing or development.

Hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Deal Review: July 22, 2013

Welcome to your Monday Biotech Deal Review for July 22, 2013! A busy week saw acquisitions of Medicago by Mitsubishi Tanabe Pharma Corporation and Allon’s acquisition by Paladin Labs.

Hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Biotech Deal Review: September 12, 2011

Welcome to your Monday Biotech Deal Review for September 12, 2011.  We hope everyone had a restful labo(u)r day long weekend, both north and south of the border.  This week’s biotech deal review is a double feature owing to last week’s holiday.  There has been a lot of activity in the past two weeks, including the announcement of a friendly takeover bid of Afexa by Valeant (Afexa is already the target of a hostile bid by Paladin).  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: August 22, 2011

Welcome to your Monday Biotech Deal Review for August 22, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP articling student Keldeagh Lindsay, who will be with us during his articles and assisting in the deal review.  Steven Zuccarelli has done a great job over the summer, and we wish him well in his final year at law school.  

There has been quite a lot of activity over the previous two weeks, with significant equity investment activity, debt financings (public and private), and mergers and acquisitions on the go.  Read on to learn more. Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 126 other followers